Search research articles
Contact Us
Filters
Showing results (201-210 of 288) with videos related to
Page
of 29
Sort By:
The New Microbiologica
|
May 21, 2013
Cross-sectional study of community serostatus to highlight undiagnosed HIV infections with oral fluid HIV-1/2 rapid test in non-conventional settings
Maria Rita Parisi, Laura Soldini, Gianmarino Vidoni, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
January 19, 2013
Efficacy and safety of lersivirine (UK-453,061) versus efavirenz in antiretroviral treatment-naive HIV-1-infected patients: week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, phase IIb trial
Pietro Vernazza, Cunshan Wang, Anton Pozniak, et al.
Journal of Medical Virology
|
October 26, 2006
Significant link between sCD30 changes and HIV viremia in patients treated with HAART
Priscilla Biswas, Alessandro Cozzi-Lepri, Fanny Delfanti, et al.
AIDS (London, England)
|
August 28, 2009
Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials
Christine Katlama, Richard Haubrich, Jacob Lalezari, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
May 8, 2007
Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results
Jose Gatell, Dominique Salmon-Ceron, Adriano Lazzarin, et al.
AIDS (London, England)
|
November 14, 2008
Patients presenting with AIDS in the HAART era: a collaborative cohort analysis
Cristina Mussini, Christian Manzardo, Margaret Johnson, et al.
HIV Clinical Trials
|
December 23, 2011
Effect of baseline characteristics on the efficacy and safety of once-daily darunavir/ ritonavir in HIV-1-infected, treatment-naïve ARTEMIS patients at week 96
Jan Fourie, Jason Flamm, Amalia Rodriguez-French, et al.
Plos One
|
August 2, 2017
Efficacy and safety of switching from branded to generic antiretrovirals in virologically suppressed HIV-infected patients
Nicola Gianotti, Andrea Poli, Laura Galli, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 20, 2006
Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial
Pedro Cahn, Jorge Villacian, Adriano Lazzarin, et al.
HIV Clinical Trials
|
May 31, 2017
Simplification to single-tablet regimen of elvitegravir, cobicistat, emtricitabine, tenofovir DF from multi-tablet ritonavir-boosted protease inhibitor plus coformulated emtricitabine and tenofovir DF regimens: week 96 results of STRATEGY-PI
Jose R Arribas, Edwin DeJesus, Jan van Lunzen, et al.
Page
of 29
Search research articles
Search
Showing results (201-210 of 288) with videos related to
Sort By:
Page
of 29
The New Microbiologica
|
May 21, 2013
Cross-sectional study of community serostatus to highlight undiagnosed HIV infections with oral fluid HIV-1/2 rapid test in non-conventional settings
Maria Rita Parisi, Laura Soldini, Gianmarino Vidoni, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
January 19, 2013
Efficacy and safety of lersivirine (UK-453,061) versus efavirenz in antiretroviral treatment-naive HIV-1-infected patients: week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, phase IIb trial
Pietro Vernazza, Cunshan Wang, Anton Pozniak, et al.
Journal of Medical Virology
|
October 26, 2006
Significant link between sCD30 changes and HIV viremia in patients treated with HAART
Priscilla Biswas, Alessandro Cozzi-Lepri, Fanny Delfanti, et al.
AIDS (London, England)
|
August 28, 2009
Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials
Christine Katlama, Richard Haubrich, Jacob Lalezari, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
May 8, 2007
Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results
Jose Gatell, Dominique Salmon-Ceron, Adriano Lazzarin, et al.
AIDS (London, England)
|
November 14, 2008
Patients presenting with AIDS in the HAART era: a collaborative cohort analysis
Cristina Mussini, Christian Manzardo, Margaret Johnson, et al.
HIV Clinical Trials
|
December 23, 2011
Effect of baseline characteristics on the efficacy and safety of once-daily darunavir/ ritonavir in HIV-1-infected, treatment-naïve ARTEMIS patients at week 96
Jan Fourie, Jason Flamm, Amalia Rodriguez-French, et al.
Plos One
|
August 2, 2017
Efficacy and safety of switching from branded to generic antiretrovirals in virologically suppressed HIV-infected patients
Nicola Gianotti, Andrea Poli, Laura Galli, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 20, 2006
Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial
Pedro Cahn, Jorge Villacian, Adriano Lazzarin, et al.
HIV Clinical Trials
|
May 31, 2017
Simplification to single-tablet regimen of elvitegravir, cobicistat, emtricitabine, tenofovir DF from multi-tablet ritonavir-boosted protease inhibitor plus coformulated emtricitabine and tenofovir DF regimens: week 96 results of STRATEGY-PI
Jose R Arribas, Edwin DeJesus, Jan van Lunzen, et al.
Page
of 29